TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8838168

Group type: EXPERIMENTAL
Intervention: Various manipulations of boundary of visual field (ellipse and circle), bodily orientation (upright and lying), and orientation of visual objects (normal, 90 degrees-tilted, and inverse) in eight experiments.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Longitudinal distance adjustments in relation to the standard distance.
Number of subjects: 8
Study: 1468285

Group type: EXPERIMENTAL
Intervention: Mexiletine (450 mg/day)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 6331138

Group type: EXPERIMENTAL
Intervention: Cronassial (20 mg daily intramuscularly for 6 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cronassial
Number of subjects: 26
Study: 30466148

Group type: EXPERIMENTAL
Intervention: Online cognitive-behavioral intervention for suicidal ideation
Number of subjects: 418
Study: 29517983

Group type: EXPERIMENTAL
Intervention: Long-arm soft fiberglass cast (Group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Long-arm traditional fiberglass (hard) cast (Group A)
Number of subjects: 100
Study: 27217287

Group type: EXPERIMENTAL
Intervention: Comprehensive exercise and education programme
Number of subjects: 1482

Group type: COMPARATOR
Intervention: Minimal intervention control
Number of subjects: 1482
Study: 25475245

Group type: EXPERIMENTAL
Intervention: Individualised self‐management support for patients and feedback on use of evidence‐based HF therapies (EBT) to physicians.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Individualised feedback on adherence to EBT for physicians.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Patient education, support, and self‐management training for diet and medication adherence by a trained nurse through 11 interactive sessions over a 4‐month period.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Medication adherence monitoring using electronic pill cap and Morisky Medication Adherence Scale (MMAS).
Number of subjects: 33
Study: 22532849

Group type: EXPERIMENTAL
Intervention: tCBT + EAP
Number of subjects: 118

Group type: COMPARATOR
Intervention: EAP alone
Number of subjects: 118
Study: 20637971

Group type: COMPARATOR
Intervention: Linagliptin 10 mg single dose
Number of subjects: 32

Group type: COMPARATOR
Intervention: Linagliptin 5 mg multiple doses
Number of subjects: 32

Group type: COMPARATOR
Intervention: Linagliptin 10 mg multiple doses
Number of subjects: 32

Group type: COMPARATOR
Intervention: Linagliptin single doses (1, 2.5, 5, 10 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Linagliptin multiple doses (2.5, 5, 10 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Linagliptin (various doses)
Number of subjects: 32
Study: 18793423

Group type: EXPERIMENTAL
Intervention: NOCOMIT-J multimodal community-based suicide prevention program
Number of subjects: 2120000

Group type: COMPARATOR
Intervention: Control regions (not specified)
Number of subjects: 2120000
Study: 15910155

Group type: EXPERIMENTAL
Intervention: Arthur (children's TV program)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Between the Lions (control group)
Number of subjects: 108
Study: 11952447

Group type: EXPERIMENTAL
Intervention: Group 0 (modified supine position immediately after spinal injection)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Group 3 (sitting position for 3 min before modified supine position)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 98
Study: 9812410

Group type: EXPERIMENTAL
Intervention: Hyperfractionation (HF) - 80.5 Gy/70 fractions/7 weeks (2 fractions x 1.15 Gy/day)
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF) - 72 Gy/45 fractions/5 weeks
Number of subjects: 1867

Group type: COMPARATOR
Intervention: Classical fractionation (CF) - 70 Gy/35 fractions/7 weeks
Number of subjects: 1867
Study: 8592998

Group type: EXPERIMENTAL
Intervention: Monitoring and dose adjustments of co-trimoxazole (5 mg/kg trimethoprim and 25 mg/kg sulfamethoxazole every 6 h for 2 days, then every 8 h for 21 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard co-trimoxazole therapy without monitoring (5 mg/kg trimethoprim and 25 mg/kg sulfamethoxazole every 6 h for 2 days, then every 8 h for 21 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Monitoring group (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 40
Study: 2650941

Group type: EXPERIMENTAL
Intervention: Sulindac 300 mg daily for one week
Number of subjects: 12
Study: 368306

Group type: EXPERIMENTAL
Intervention: 10 percent aqueous phenylephrine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 10 percent viscous phenylephrine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 2.5 percent solution (double blind study)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1 percent cyclopentolate
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1 percent tropicamide
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combination of drugs (protocol at United Hospitals Medical Center)
Number of subjects: 48
Study: 31410514

Group type: EXPERIMENTAL
Intervention: Protector™ Laryngeal Mask Airway (LMA)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 78
Study: 30103692

Group type: EXPERIMENTAL
Intervention: Implementation of an ACP-guideline with training and supervision of project teams and staff for 12 months.
Number of subjects: 0
Study: 26798083

Group type: EXPERIMENTAL
Intervention: 32G needle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 90° needle insertion angle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wait times of minimum 3 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injections in the abdomen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injection volume up to 800 µL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thin needle
Number of subjects: 0
Study: 24561752

Group type: EXPERIMENTAL
Intervention: Hct strategy 34.5%-39.0% (mid)
Number of subjects: 22474

Group type: COMPARATOR
Intervention: Hct strategy 30.0%-34.5% (low)
Number of subjects: 22474
Study: 21792215

Group type: EXPERIMENTAL
Intervention: Whey hydrolysate
Number of subjects: 11

Group type: COMPARATOR
Intervention: Alpha-lactalbumin, whey isolate, caseinoglycomacropeptide
Number of subjects: 11
Study: 19281585

Group type: EXPERIMENTAL
Intervention: 10 mg mifepristone daily for three months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17229243

Group type: EXPERIMENTAL
Intervention: Immediate-release omeprazole (IR-OME)
Number of subjects: 54
Study: 15580149

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study: 12001978

Group type: EXPERIMENTAL
Intervention: Advice to increase soluble fibre intake to 8.0 g day(‐1) (fruit, vegetables and oats)
Number of subjects: 753
Study: 9174231

Group type: EXPERIMENTAL
Intervention: Bottle feeding
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bolus gavage feeding
Number of subjects: 30

Group type: COMPARATOR
Intervention: Slow gavage feeding
Number of subjects: 30
Study: 7892424

Group type: EXPERIMENTAL
Intervention: Nitrous oxide 40%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nitrous oxide 10%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nitrous oxide 5%
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (0%)
Number of subjects: 12
Study: 3228817

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29485676

Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention (PFI)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Both conditions (PFI and control)
Number of subjects: 164
Study: 27804310

Group type: EXPERIMENTAL
Intervention: 200 mg oral mifepristone plus 400 μg misoprostol per vaginally concurrently (group A)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Misoprostol administered after 48 hours (group B)
Number of subjects: 200
Study: 25631171

Group type: EXPERIMENTAL
Intervention: Bidirectional barbed sutures
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard sutures
Number of subjects: 50
Study: 24080137

Group type: EXPERIMENTAL
Intervention: Chinese version of the My Trauma Recovery (CMTR) website intervention
Number of subjects: 183
Study: 21169226

Group type: EXPERIMENTAL
Intervention: DHA supplementation (1200 mg/d)
Number of subjects: 12
Study: 18460568

Group type: EXPERIMENTAL
Intervention: Triflusal (two dose levels)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triflusal (800 mum of the main metabolite)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triflusal (200 mum of 2-hydroxy-4-trifluoromethylbenzoic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17290957

Group type: EXPERIMENTAL
Intervention: Participatory intervention to prevent workplace violence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline and post-intervention survey
Number of subjects: 0
Study: 14649507

Group type: EXPERIMENTAL
Intervention: Horsechestnut intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategies to overcome barriers
Number of subjects: 0
Study: 10715040

Group type: EXPERIMENTAL
Intervention: SH U 508A-enhanced Doppler US
Number of subjects: 198

Group type: COMPARATOR
Intervention: Nonenhanced Doppler US
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: SH U 508A
Number of subjects: 198
Study: 8873586

Group type: EXPERIMENTAL
Intervention: Desmin 100 mg once daily by subcutaneous route (36 patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Desmin 100 mg twice a day by subcutaneous route (33 patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Desmin 200 mg once daily by intramuscular route (31 patients)
Number of subjects: 100
Study: 8156369

Group type: EXPERIMENTAL
Intervention: Abdominal resection rectopexy and pelvic floor repair
Number of subjects: 20

Group type: COMPARATOR
Intervention: Perineal rectosigmoidectomy and pelvic floor repair
Number of subjects: 20
Study: 2895125

Group type: EXPERIMENTAL
Intervention: Nizatidine 75 mg bid
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg bid
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg bid
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg qid
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29759105

Group type: EXPERIMENTAL
Intervention: Asian breakfast foods (medium to high GI)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Western breakfast foods (low GI)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Correlation of GI values with dietary components
Number of subjects: 19
Study: 28399054

Group type: EXPERIMENTAL
Intervention: Tdap vaccination during pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not vaccinated with Tdap during pregnancy)
Number of subjects: 0
Study: 24725308

Group type: EXPERIMENTAL
Intervention: Care transition intervention including pre-discharge education and post-discharge telephone nurse coaching with home telemonitoring.
Number of subjects: 1500
Study: 22960196

Group type: EXPERIMENTAL
Intervention: GIP infusion [2.0 pmol kg(‐1) min(‐1) for 240 min]
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 19952762

Group type: EXPERIMENTAL
Intervention: rs1447295 A allele
Number of subjects: 3822

Group type: EXPERIMENTAL
Intervention: DG8S737 -8 allele
Number of subjects: 3822

Group type: EXPERIMENTAL
Intervention: rs1447295 A allele in familial prostate cancer
Number of subjects: 3822

Group type: EXPERIMENTAL
Intervention: DG8S737 -8 allele in familial prostate cancer
Number of subjects: 3822

Group type: EXPERIMENTAL
Intervention: rs1447295 A allele for aggressive tumours (Gleason score 8 or more)
Number of subjects: 3822

Group type: EXPERIMENTAL
Intervention: rs1447295 A allele for tumours with Gleason score 7 and below
Number of subjects: 3822
Study: 18001246

Group type: EXPERIMENTAL
Intervention: Sub-tenon triamcinolone acetonide (STA) injection
Number of subjects: 0
Study: 16250568

Group type: EXPERIMENTAL
Intervention: Emdogain (Biora) combined with surgical treatment (SPP flap)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Surgical treatment alone (SPP)
Number of subjects: 153
Study: 12404673

Group type: EXPERIMENTAL
Intervention: Cholecystokinin tetrapeptide (CCK‐4) infusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 24
Study: 9803700

Group type: EXPERIMENTAL
Intervention: Escalating schedule (n = 20)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Escalating schedule with start-up bonuses (n = 20)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Noncontingent schedule (n = 19)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both contingent interventions (escalating schedule and escalating schedule with start-up bonuses)
Number of subjects: 59
Study: 7975833

Group type: EXPERIMENTAL
Intervention: HIV‐1LAV gp160 live recombinant vaccinia virus priming followed by a booster injection with a baculovirus‐expressed HIV‐1LAV recombinant gp160 candidate vaccine
Number of subjects: 12
Study: 2656263

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 0
Study: 29886135

Group type: EXPERIMENTAL
Intervention: Moderate Intensity Exercise (MIE)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: High Intensity Exercise (HIE)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 94
Study: 29033099

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (25 mg/m2 IV every 21 days) plus prednisone (10 mg daily) with custirsen (640 mg IV on days 1, 8, and 15, plus three previous loading doses)
Number of subjects: 635

Group type: COMPARATOR
Intervention: Cabazitaxel (25 mg/m2 IV every 21 days) plus prednisone (10 mg daily)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Custirsen group
Number of subjects: 635

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 635
Study: 25207707

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus dexmedetomidine (BvD group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus fentanyl (BvF group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bupivacaine (Bv group)
Number of subjects: 90
Study: 23436098

Group type: EXPERIMENTAL
Intervention: INVEST
Number of subjects: 10
Study: 21505304

Group type: EXPERIMENTAL
Intervention: Drug Conservation (DC) arm
Number of subjects: 200

Group type: COMPARATOR
Intervention: Viral Suppression (VS) arm
Number of subjects: 200
Study: 18332641

Group type: EXPERIMENTAL
Intervention: Routine skin cultures
Number of subjects: 497
Study: 17256437

Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition (PPN) for 7 days perioperatively
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard care (oral diet reintroduction on the fourth postoperative day)
Number of subjects: 27
Study: 12939440

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Number of subjects: 4

Group type: COMPARATOR
Intervention: Low-carbohydrate diet
Number of subjects: 4
Study: 10862159

Group type: EXPERIMENTAL
Intervention: Amiloride nebulized solution three times daily for 6 months
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo nebulized solution three times daily for 6 months
Number of subjects: 137
Study: 9112877

Group type: EXPERIMENTAL
Intervention: Hospital-based exercise rehabilitation program (treadmill walking three times a week for one hour/visit)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Home-based exercise program (instructed to walk at least three times a week, weekly contact for encouragement)
Number of subjects: 20
Study: 1555549

Group type: EXPERIMENTAL
Intervention: Intrathecal pethidine (1 mg kg‐1 of 5% pethidine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain bupivacaine (3.5 ml of 0.5% plain bupivacaine)
Number of subjects: 0
Study: 3979485

Group type: EXPERIMENTAL
Intervention: Inspiratory resistive breathing training
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no inspiratory resistance)
Number of subjects: 27
Study: 31020642

Group type: EXPERIMENTAL
Intervention: 1 mm thick connective tissue graft (CTG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 mm thick connective tissue graft (CTG)
Number of subjects: 30
Study: 28903966

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT) followed by conventional medical therapy as required
Number of subjects: 718

Group type: COMPARATOR
Intervention: Topical medication without laser therapy
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 718

Group type: COMPARATOR
Intervention: Topical medication
Number of subjects: 718
Study: 25995393

Group type: EXPERIMENTAL
Intervention: Mueller manoeuvre (MM)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Inspiration through a threshold load (ITH)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: End‐expiratory central apnoea (AP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normal breathing (NB)
Number of subjects: 44
Study: 24708818

Group type: EXPERIMENTAL
Intervention: Low-sodium diet (<100 mmol/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-sodium intake (additional 120 mmol sodium tablets)
Number of subjects: 20
Study: 22607767

Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/d
Number of subjects: 96

Group type: COMPARATOR
Intervention: Metformin 1000 mg/d
Number of subjects: 96
Study: 20518615

Group type: EXPERIMENTAL
Intervention: meloxicam 7.5 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 18571083

Group type: EXPERIMENTAL
Intervention: DisCoVisc (hyaluronic acid 1.6%‐chondroitin sulfate 4.0%)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Viscoat and Provisc (sodium hyaluronate 3.0%‐chondroitin sulfate 4.0% and sodium hyaluronate 1.0%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DisCoVisc
Number of subjects: 100

Group type: COMPARATOR
Intervention: Viscoat and Provisc
Number of subjects: 100
Study: 16003515

Group type: EXPERIMENTAL
Intervention: carteolol 2% LA once daily for 2 months
Number of subjects: 23

Group type: COMPARATOR
Intervention: carteolol 2% regular twice daily for 2 months
Number of subjects: 23
Study: 12501943

Group type: EXPERIMENTAL
Intervention: Patellar taping
Number of subjects: 15
Study: 10599713

Group type: EXPERIMENTAL
Intervention: E2 and P replacement (2.30 mg/kg x day E2 and 21.20 mg/kg x day P, iv)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No replacement
Number of subjects: 30
Study: 8605790

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1 mg/kg followed by an infusion of 1.5 mg/kg/hr for 24 hrs)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 16
Study: 1826961

Group type: EXPERIMENTAL
Intervention: RT + SR 2508
Number of subjects: 242

Group type: COMPARATOR
Intervention: RT
Number of subjects: 242
Study: 6128019

Group type: EXPERIMENTAL
Intervention: Triprolidine (10 mg sustained release)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no antihistamine)
Number of subjects: 0
Study: 31046620

Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention for sit-to-stand movement
Number of subjects: 91

Group type: COMPARATOR
Intervention: Baseline factors in always-able subgroup
Number of subjects: 91
Study: 28922099

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, Lactobacillus fermentum; 2 × 10^9 colony‐forming units/g each; n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 40
Study: 25023068

Group type: EXPERIMENTAL
Intervention: Mirror therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 34
Study: 24705469

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 39

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 39
Study: 20392523

Group type: EXPERIMENTAL
Intervention: Acellular dermis
Number of subjects: 42

Group type: COMPARATOR
Intervention: Temporalis fascia
Number of subjects: 42
Study: 19707782

Group type: EXPERIMENTAL
Intervention: Rowing in water
Number of subjects: 8
Study: 18005415

Group type: EXPERIMENTAL
Intervention: Confrontational counselling delivered by a respiratory nurse combined with nortriptyline for smoking cessation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health education and promotion delivered by a respiratory nurse combined with nortriptyline for smoking cessation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual delivered by the GP
Number of subjects: 0
Study: 15572850

Group type: EXPERIMENTAL
Intervention: Oral zafirlukast (40 mg/day) in addition to budesonide for 6 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo in addition to budesonide for 6 weeks
Number of subjects: 21
Study: 11359426

Group type: EXPERIMENTAL
Intervention: Citrus red mite (Panonychus citri)
Number of subjects: 7254

Group type: EXPERIMENTAL
Intervention: Positive skin responses to the citrus red mite
Number of subjects: 7254

Group type: EXPERIMENTAL
Intervention: ELISA inhibition tests
Number of subjects: 7254
Study: 8995587

Group type: EXPERIMENTAL
Intervention: Suramin treatment
Number of subjects: 41
Study: 8432154

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 88

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 88
Study: 3434006

Group type: EXPERIMENTAL
Intervention: Estradiol valerate (2.0 mg/day)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Norethisterone acetate (5.0 mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (before treatment)
Number of subjects: 52
Study: 29730623

Group type: EXPERIMENTAL
Intervention: Family Nurse Partnership (FNP) home visiting programme added to usual care
Number of subjects: 161

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 161
Study: 26724456

Group type: EXPERIMENTAL
Intervention: Vascularized bone grafting fixed by biodegradable magnesium screws
Number of subjects: 48

Group type: COMPARATOR
Intervention: Vascularized bone grafting without fixation (Control)
Number of subjects: 48